12,378 TG Therapeutics, Inc. $TGTX Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue reduced its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 19.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 50,024 shares of the biopharmaceutical company’s stock after selling 12,378 shares during the period. State of Alaska Department of Revenue’s holdings in TG Therapeutics were worth $2,788,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Chiron Capital Management LLC boosted its stake in shares of TG Therapeutics by 10.5% during the third quarter. Chiron Capital Management LLC now owns 4,200 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 400 shares during the period. GAMMA Investing LLC grew its holdings in shares of TG Therapeutics by 15.4% during the third quarter. GAMMA Investing LLC now owns 5,929 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 789 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of TG Therapeutics by 45.8% during the third quarter. Farther Finance Advisors LLC now owns 993 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 312 shares during the last quarter. Cim Investment Management Inc. acquired a new position in TG Therapeutics in the 2nd quarter valued at about $349,000. Finally, Envestnet Portfolio Solutions Inc. increased its position in TG Therapeutics by 24.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 21,192 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 4,215 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Laurence Charney sold 5,000 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the transaction, the director directly owned 168,640 shares of the company’s stock, valued at $9,268,454.40. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 8.87% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have commented on TGTX. HC Wainwright reaffirmed a “buy” rating and set a $78.00 price objective on shares of TG Therapeutics in a research note on Tuesday, September 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $83.00 price objective on shares of TG Therapeutics in a research report on Monday, June 22nd. Weiss Ratings upgraded TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Bank of America lifted their target price on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. Finally, B. Riley Financial boosted their target price on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a report on Monday, July 27th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, TG Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $63.00.

TG Therapeutics Stock Down 3.6%

Shares of TG Therapeutics stock opened at $53.97 on Friday. The company has a market cap of $8.26 billion, a P/E ratio of 19.70, a PEG ratio of 2.28 and a beta of 1.80. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. TG Therapeutics, Inc. has a one year low of $26.76 and a one year high of $59.30. The firm has a fifty day moving average of $54.27 and a two-hundred day moving average of $48.12.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.26). The firm had revenue of $240.34 million during the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%. The firm’s revenue was up 70.2% on a year-over-year basis. During the same quarter last year, the business posted $0.17 EPS. On average, analysts forecast that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell-mediated diseases, including multiple sclerosis and B-cell malignancies. The company’s research and development activities center on antibody-based therapies designed to target B cells and related immune pathways.

TG Therapeutics’ principal marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.